Research Topics
| Timothy CardozoSummaryAffiliation: New York University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodiesTimothy Cardozo
New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
AIDS Res Hum Retroviruses 25:441-50. 2009..More importantly, these calculations demonstrate that globally relevant, structurally conserved epitopes are present in the sequence variable V3 loop...- Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjectsEvgeny Shmelkov
Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York, United States of America
PLoS ONE 6:e27279. 2011.... - Quantitative assessment of masking of neutralization epitopes in HIV-1Alpna Agarwal
Department of Pharmacology, New York University School of Medicine, 550 First Avenue MSB 497, New York, NY 10016, USA
Vaccine 29:6736-41. 2011..These results have important implications for rational design of vaccines designed to induce neutralizing Abs by revealing epitopes that are minimally masked and maximally reactive with neutralizing Abs... - Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loopDavid Almond
Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York 10016, USA
AIDS Res Hum Retroviruses 26:717-23. 2010..From a structural point of view, there appears to be less diversity in this region of the HIV-1 "principle neutralizing domain" than previously appreciated... - Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structureMiroslaw K Gorny
Department of Pathology, New York University School of Medicine, New York, New York, United States of America
PLoS ONE 6:e27780. 2011..This will be useful information for designing vaccine immunogen inducing cross-neutralizing Abs... - Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesJames Swetnam
Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America
PLoS ONE 5:e15994. 2010..Our results suggest one way to quantify and compare the magnitude of the conservation... - Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNASusan Zolla-Pazner
Veterans Affairs Medical Center, New York, NY, USA
J Virol 85:9887-98. 2011.... 
Structural basis for coreceptor selectivity by the HIV type 1 V3 loopTimothy Cardozo
Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
AIDS Res Hum Retroviruses 23:415-26. 2007..The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression...
Conserved structural elements in the V3 crown of HIV-1 gp120Xunqing Jiang
Department of Biochemistry, New York University School of Medicine, New York, New York, USA
Nat Struct Mol Biol 17:955-61. 2010..As these regions are targeted by cross-clade neutralizing human antibodies, they provide a blueprint for the design of vaccine immunogens that could elicit broadly cross-reactive protective antibodies...- Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop AntibodiesDavid Almond
Department of Pharmacology, New York University School of Medicine NYSoM, New York, NY 10016, USA
Adv Virol 2012:803535. 2012..As antibodies to a variable loop were recently identified as an inverse correlate of risk for HIV infection, the structure-function relationships discussed in this study may have relevance to HIV vaccine research... - Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designSusan Zolla-Pazner
Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
Nat Rev Immunol 10:527-35. 2010..Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1... - Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and CKlara Felsovalyi
Department of Pharmacology, New York University School of Medicine and the New York Veterans Affairs Medical Center, New York, New York 10016, USA
AIDS Res Hum Retroviruses 22:703-8. 2006..This lowest limit was 10(16). Although theoretically a p-value cannot be equal to 0.0, the p-value for the comparisons in question can be intuitively considered to be extremely small, or approximately 0.0.)... - Structural determinants of PERK inhibitor potency and selectivityHong Wang
Department of Pharmacology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
Chem Biol Drug Des 76:480-95. 2010..Interestingly, the activation loop contact is required for PERK selectivity to emerge. Understanding these structure-activity relationships may accelerate rational PERK inhibitor design... - Modeling the interaction between aldolase and the thrombospondin-related anonymous protein, a key connection of the malaria parasite invasion machineryCarlos A Buscaglia
Michael Heidelberg Division of Pathology of Infectious Diseases, Department of Pathology, New York University School of Medicine, New York, USA
Proteins 66:528-37. 2007..Enzymatic and TRAP-binding assays using mutant PfAldo molecules strongly support the overall structural model. These results might provide the initial framework for the identification of novel antiparasitic compounds...